Study to Learn About How the Study Medicines Called PF-07976016 and PF-06882961 Are Taken Up by the Body, and if Either of Them Change How the Body Processes the Other Medicine in Otherwise Healthy Adults With Overweight or Obesity

Phase 1 Terminated 21 enrolled Pfizer

NaSingle-groupOpen-labelBasic science

Summary

The purpose of this study is to see how two study medicines, PF-07976016 and danuglipron, taken together affect the level of each other in the blood of participants who have overweight or obesity. The total number of weeks of the study is up to approximately 22 weeks (5.5 months).

Timeline

Start: 2025-03-13
Primary completion: 2025-05-01
Completion: 2025-05-20

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Danuglipron	Small molecule	—	Oral
Subject	PF-07976016	Unknown	—	Oral

Study to Learn About How the Study Medicines Called PF-07976016 and PF-06882961 Are Taken Up by the Body, and if Either of Them Change How the Body Processes the Other Medicine in Otherwise Healthy Adults With Overweight or Obesity

Summary

Timeline

Drugs

Indications